Article Text

PDF
Extended report
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
  1. Gisela Ruiz Heiland1,
  2. Karin Zwerina1,
  3. Wolfgang Baum1,
  4. Trayana Kireva1,
  5. Jörg H Distler1,
  6. Mario Grisanti2,
  7. Frank Asuncion2,
  8. Xiadong Li2,
  9. Michael Ominsky2,
  10. William Richards2,
  11. Georg Schett1,
  12. Jochen Zwerina1
  1. 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
  2. 2Amgen Incorporated, Thousand Oaks, California, USA
  1. Correspondence to Jochen Zwerina, Department of Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, D-91054 Erlangen, Germany; jochen.zwerina{at}uk-erlangen.de

Abstract

Introduction Inflammation is a major risk factor for systemic bone loss. Proinflammatory cytokines like tumour necrosis factor (TNF) affect bone homeostasis and induce bone loss. It was hypothesised that impaired bone formation is a key component in inflammatory bone loss and that Dkk-1, a Wnt antagonist, is a strong inhibitor of osteoblast-mediated bone formation.

Methods TNF transgenic (hTNFtg) mice were treated with neutralising antibodies against TNF, Dkk-1 or a combination of both agents. Systemic bone architecture was analysed by bone histomorphometry. The expression of β-catenin, osteoprotegerin and osteocalcin was analysed. In vitro, primary osteoblasts were stimulated with TNF and analysed for their metabolic activity and expression of Dkk-1 and sclerostin. Sclerostin expression and osteocyte death upon Dkk-1 blockade were analysed in vivo.

Results Neutralisation of Dkk-1 completely protected hTNFtg mice from inflammatory bone loss by preventing TNF-mediated impaired osteoblast function and enhanced osteoclast activity. These findings were accompanied by enhanced skeletal expression of β-catenin, osteocalcin and osteoprotegerin. In vitro, TNF rapidly increased Dkk-1 expression in primary osteoblasts and effectively blocked osteoblast differentiation. Moreover, blockade of Dkk-1 not only rescued impaired osteoblastogenesis but also neutralised TNF-mediated sclerostin expression in fully differentiated osteoblasts in vitro and in vivo.

Conclusions These findings indicate that low bone formation and expression of Dkk-1 trigger inflammatory bone loss. Dkk-1 blocks osteoblast differentiation, induces sclerostin expression and leads to osteocyte death. Inhibition of Dkk-1 may thus be considered as a potent strategy to protect bone from inflammatory damage.

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by the Interdisziplinäres Zentrum für Klinische Forschung Erlangen Project A34 (to GS and JZ), Deutsche Forschungsgemeinschaft Grant FOR 661 (to GS) and SFB 423 (to JZ and GS) and the European Union projects Masterswitch, Adipoa and Kinacept. This study was also supported by the Focus Programm SPP 1468 ‘Osteoimmunology - IMMUNOBONE – a program to unravel the mutual interactions between the immune system and bone’ of the Deutsche Forschungsgesellschaft.

  • Competing interests GS and JZ received speaker's fees from Amgen Incorporated. MG, FA, XL, MO and WR are employees of Amgen Incorporated.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.